Cancer Research and Treatment

HTA and Gastric Cancer: Evaluating Alternatives in Third- and Fourth-Line Patients

Lucrezia Ferrario, Federica Asperti, Giuseppe Aprile, Jacopo Giuliani

International Journal of Environmental Research and Public Health.2023; 20(3): 2107. CrossRef

Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach

Tae-Han Kim, In-Ho Kim, Seung Joo Kang, Miyoung Choi, Baek-Hui Kim, Bang Wool Eom, Bum Jun Kim, Byung-Hoon Min, Chang In Choi, Cheol Min Shin, Chung Hyun Tae, Chung sik Gong, Dong Jin Kim, Arthur Eung-Hyuck Cho, Eun Jeong Gong, Geum Jong Song, Hyeon-Su Im

Journal of Gastric Cancer.2023; 23(1): 3. CrossRef

A Comprehensive and Comparative Review of Global Gastric Cancer Treatment Guidelines

Sang Soo Eom, Wonyoung Choi, Bang Wool Eom, Sin Hye Park, Soo Jin Kim, Young Il Kim, Hong Man Yoon, Jong Yeul Lee, Chan Gyoo Kim, Hark Kyun Kim, Myeong-Cherl Kook, Il Ju Choi, Young-Woo Kim, Young Iee Park, Keun Won Ryu

Journal of Gastric Cancer.2022; 22(1): 3. CrossRef

Current therapeutic options for gastric adenocarcinoma

C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad

Saudi Journal of Biological Sciences.2021; 28(9): 5371. CrossRef

What is the value of third‐line chemotherapy in advanced gastroesophageal cancer? A 5‐year retrospective analysis at a single center

Justina Yick Ching Lam, Su Pin Choo, David Wai‐Meng Tai, Iain Bee Huat Tan, Chee Kian Tham, Wen Hsin Koo, Simon Yew Kuang Ong, Soo Fan Ang, Clarinda Wei Ling Chua, Dawn Qingqing Chong, Patrick Tze Hern Teo, Christabel Jing Zhi Lee, Samuel Cheng En Ee, Mat

Asia-Pacific Journal of Clinical Oncology.2020; 16(1): 23. CrossRef

Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach

Journal of Gastric Cancer.2019; 19(1): 1. CrossRef

Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights

Giandomenico Roviello, Alberto D’Angelo, Raheleh Roudi, Roberto Petrioli, Enrico Mini

Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study

In Sil Choi, Mihong Choi, Ju Hyun Lee, Jee Hyun Kim, Koung Jin Suh, Ji Yun Lee, Beodeul Kang, Ji-Won Kim, Se-Hyun Kim, Jin Won Kim, Jeong-Ok Lee, Yu Jung Kim, Soo-Mee Bang, Jong Seok Lee, Keun-Wook Lee, Ju-Seog Lee

The role of third-line chemotherapy in recurrent or metastatic gastric cancer

Yong Won Choi, Mi Sun Ahn, Geum Sook Jeong, Hyun Woo Lee, Seong Hyun Jeong, Seok Yun Kang, Joon Seong Park, Jin-Hyuk Choi, Seung Soo Sheen

Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends

P. Edwards, M. Davidson, V. Calamai, D. Cunningham, N. Starling

Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes

Takashi Nishimura, Satoru Iwasa, Kengo Nagashima, Natsuko Okita, Atsuo Takashima, Yoshitaka Honma, Ken Kato, Tetsuya Hamaguchi, Yasuhide Yamada, Yasuhiro Shimada, Narikazu Boku

Advanced gastric cancer: is there an optimal chemotherapy regimen?

Kalliopi Andrikou, Massimiliano Salati, Annalisa Fontana, Andrea Spallanzani, Stefania Pipitone, Fabio Gelsomino, Monica Barbolini, Stefano Cascinu

Expert Review of Quality of Life in Cancer Care.2017; 2(2): 123. CrossRef

Third-line systemic treatment versus best supportive care for advanced/metastatic gastric cancer: A systematic review and meta-analysis

Wing-lok Chan, Kwok-keung Yuen, Steven Wai-kwan Siu, Ka-on Lam, Dora Lai-wan Kwong

Critical Reviews in Oncology/Hematology.2017; 116: 68. CrossRef

Third-line chemotherapy in advanced gastric cancer

Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer?

Massimiliano Salati, Katia Di Emidio, Vittoria Tarantino, Stefano Cascinu

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy

Valentina Fanotto, Mario Uccello, Irene Pecora, Lorenza Rimassa, Francesco Leone, Gerardo Rosati, Daniele Santini, Riccardo Giampieri, Samantha Di Donato, Gianluca Tomasello, Nicola Silvestris, Filippo Pietrantonio, Francesca Battaglin, Antonio Avallone,

Metastatic gastric cancer treatment: Second line and beyond

Marwan Ghosn, Samer Tabchi, Hampig Raphael Kourie, Mustapha Tehfe

World Journal of Gastroenterology.2016; 22(11): 3069. CrossRef

A Phase I study of cabazitaxel in patients with advanced gastric cancer who have failed prior chemotherapy (GASTANA)

Yoon-Koo Kang, Baek-Yeol Ryoo, Shinkyo Yoon, Lin Shen, Jooyun Lee, Chenlu Wei, Yu Zhou, Min-Hee Ryu

Cancer Chemotherapy and Pharmacology.2015; 75(2): 309. CrossRef

Impact of the availability of active cytotoxic agents on the survival of patients with advanced gastric cancer

BYUNG HA CHO, HYE SOOK HAN, JIHYUN KWON, JOUNG-HO HAN, SOON MAN YOON, DAE HOON KIM, HYO YUNG YUN, KI HYEONG LEE, SEI JIN YOUN, SEUNG TAIK KIM

Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma

Therapeutic Advances in Gastroenterology.2015; 8(4): 189. CrossRef

Chemotherapy beyond second-line in advanced gastric cancer

World Journal of Gastroenterology.2015; 21(29): 8811. CrossRef

Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study

Yulong Zheng, Weijia Fang, Chenyu Mao, Joing Qian, Peng Zhao, Xiaochen Zhang, Haiping Jiang, Yi Zheng, Nong Xu

Cancer Chemotherapy and Pharmacology.2014; 74(3): 503. CrossRef